多发性骨髓瘤中的MRD:从加速批准的早期终点到MRD驱动的治疗和临床管理
Ola Landgren1, Rafat Abonour1, Dickran Kazandjian1
1Sylvester Comprehensive Cancer Center, Sylvester Myeloma Institute, University of Miami, Miami, FL.
Seminars in hematology
|February 24, 2026
概括
最小残留疾病 (MRD) 评估现在是FDA认可的多发性骨髓瘤早期终点,改变了治疗和监管途径. 未来的基于血液的MRD测试将提高患者的实时监测和精确护理.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 最小残留疾病 (MRD) 评估已经从预后生物标志物演变为多发性骨髓瘤研究和临床实践的关键因素.
- 基因组学,免疫类型定型和高灵敏度测试方面的进展推动了MRD评估的进展.
- 美国食品和药物管理局 (FDA) 现在将MRD视为早期终点,从而实现了加速批准的途径.
研究的目的:
- 突出MRD评估在多发性骨髓瘤中的变革性影响.
- 讨论支持MRD作用的证据基础,包括EVIDENCE元分析和I2TEAMM研究.
- 探索MRD导向治疗策略的影响以及基于血液的MRD技术的未来方向.
主要方法:
- 对元分析 (EVIDENCE) 和前性试验 (PERSEUS,MIDAS,ADVANCE) 的审查.
- 对FDA承认MRD作为早期终点的分析.
- 讨论在MRD检测方面的技术进步.
主要成果:
- MRD评估已经过渡到FDA认可的多发性骨髓瘤早期终点.
- 前性试验证明了MRD引导治疗调整的可行性.
- 证据元分析和I2TEAMM研究为这一转变提供了关键证据.
结论:
- MRD评估正在彻底改变多发性骨髓瘤治疗方法和监管过程.
- 以MRD为指导的治疗强化和缓解正在成为标准的临床实践.
- 基于血液的MRD技术的发展将进一步提高精准医学和多发性骨髓瘤患者的护理.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.8K
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
764
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).